Experience of Traditional Chinese and Western Medicine in the Treatment of IgA Nephropathy

Authors

  • Fuyu Chen Shaanxi University of Chinese medicine, Xianyang 712046, Shaanxi, China
  • Xinbo Yang The Second Affiliated Hospital of Shaanxi University of Chinese medicine, Xianyang 712046, Shaanxi, China

DOI:

https://doi.org/10.53469/jcmp.2025.07(07).38

Keywords:

IgAnephropathy, Glucocorticoids, Immunosuppressant, Traditional Chinese and drugs, Cause of diseased and pathogenesis

Abstract

IgA nephropathy (hereinafter referred to as IgAN) is the most common primary glomerular disease in the world at present. Its pathogenesis is not clear and its clinical symptoms are diverse. The treatment is mainly glucocorticoids, immunosuppressants, antihypertensive and anticoagulant treatment. There is no IgAN disease in traditional Chinese medicine. According to its clinical manifestations, it can It is classified in the categories of “hematuria” and “edema”. Most of the pathogenesis is based on the deficient root and excessive branch, in the process of the disease, there are both stasis blood pattern, wind evil and dampness-heat and other pathogenic factors. It also puts forward the treatment principles such as supporting vital Qiand expelling evils, activating blood to resolve stasis, clearing heat and eliminating dampness, benefiting qi and nourishing yin, paying attention to the overall concept, putting people-oriented, treating both the symptoms and root and branch, and improving the prognosis and long-term survival quality of patients. It has significant advantages in terms of quantity. Therefore, this article aims to briefly discuss the clinical experience of traditional Chinese and Western medicine treatment of IgAN and provide reference for clinical treatment of IgAN.

Downloads

Published

2025-07-31

How to Cite

Chen, F., & Yang, X. (2025). Experience of Traditional Chinese and Western Medicine in the Treatment of IgA Nephropathy. Journal of Contemporary Medical Practice, 7(7), 195–201. https://doi.org/10.53469/jcmp.2025.07(07).38